1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2014

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 569 pages

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014’, provides an overview of the Multiple Myeloma (Kahler's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Myeloma (Kahler's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
Introduction 7
Multiple Myeloma (Kahler's Disease) Overview 8
Therapeutics Development 9
Multiple Myeloma (Kahler's Disease) - Therapeutics under Development by Companies 11
Multiple Myeloma (Kahler's Disease) - Therapeutics under Investigation by Universities/Institutes 20
Multiple Myeloma (Kahler's Disease) - Pipeline Products Glance 23
Multiple Myeloma (Kahler's Disease) - Products under Development by Companies 27
Multiple Myeloma (Kahler's Disease) - Products under Investigation by Universities/Institutes 36
Multiple Myeloma (Kahler's Disease) - Companies Involved in Therapeutics Development 38
Multiple Myeloma (Kahler's Disease) - Therapeutics Assessment 129
Drug Profiles 152
Multiple Myeloma (Kahler's Disease) - Recent Pipeline Updates 404
Multiple Myeloma (Kahler's Disease) - Dormant Projects 533
Multiple Myeloma (Kahler's Disease) - Discontinued Products 539
Multiple Myeloma (Kahler's Disease) - Product Development Milestones 540
Appendix 550

List of Tables

Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2014 27
Number of Products under Development for Multiple Myeloma (Kahler's Disease) - Comparative Analysis, H1 2014 28
Number of Products under Development by Companies, H1 2014 30
Number of Products under Development by Companies, H1 2014 (Contd..1) 31
Number of Products under Development by Companies, H1 2014 (Contd..2) 32
Number of Products under Development by Companies, H1 2014 (Contd..3) 33
Number of Products under Development by Companies, H1 2014 (Contd..4) 34
Number of Products under Development by Companies, H1 2014 (Contd..5) 35
Number of Products under Development by Companies, H1 2014 (Contd..6) 36
Number of Products under Development by Companies, H1 2014 (Contd..7) 37
Number of Products under Investigation by Universities/Institutes, H1 2014 39
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 40
Comparative Analysis by Late Stage Development, H1 2014 41
Comparative Analysis by Clinical Stage Development, H1 2014 42
Comparative Analysis by Early Stage Development, H1 2014 43
Comparative Analysis by Unknown Stage Development, H1 2014 44
Products under Development by Companies, H1 2014 45
Products under Development by Companies, H1 2014 (Contd..1) 46
Products under Development by Companies, H1 2014 (Contd..2) 47
Products under Development by Companies, H1 2014 (Contd..3) 48
Products under Development by Companies, H1 2014 (Contd..4) 49
Products under Development by Companies, H1 2014 (Contd..5) 50
Products under Development by Companies, H1 2014 (Contd..6) 51
Products under Development by Companies, H1 2014 (Contd..7) 52
Products under Development by Companies, H1 2014 (Contd..8) 53
Products under Investigation by Universities/Institutes, H1 2014 54
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 55
Multiple Myeloma (Kahler's Disease) - Pipeline by Johnson and Johnson, H1 2014 56
Multiple Myeloma (Kahler's Disease) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 57
Multiple Myeloma (Kahler's Disease) - Pipeline by Amgen Inc., H1 2014 58
Multiple Myeloma (Kahler's Disease) - Pipeline by Eli Lilly and Company, H1 2014 59
Multiple Myeloma (Kahler's Disease) - Pipeline by GlaxoSmithKline plc, H1 2014 60
Multiple Myeloma (Kahler's Disease) - Pipeline by Seattle Genetics, Inc., H1 2014 61
Multiple Myeloma (Kahler's Disease) - Pipeline by Biotest AG, H1 2014 62
Multiple Myeloma (Kahler's Disease) - Pipeline by Merck and Co., Inc., H1 2014 63
Multiple Myeloma (Kahler's Disease) - Pipeline by Gamida Cell Ltd., H1 2014 64
Multiple Myeloma (Kahler's Disease) - Pipeline by BioLineRx, Ltd., H1 2014 65
Multiple Myeloma (Kahler's Disease) - Pipeline by Amorfix Life Sciences Ltd., H1 2014 66
Multiple Myeloma (Kahler's Disease) - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 67
Multiple Myeloma (Kahler's Disease) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 68
Multiple Myeloma (Kahler's Disease) - Pipeline by Novartis AG, H1 2014 69
Multiple Myeloma (Kahler's Disease) - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 70
Multiple Myeloma (Kahler's Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 71
Multiple Myeloma (Kahler's Disease) - Pipeline by Sigma-Tau S.p.A., H1 2014 72
Multiple Myeloma (Kahler's Disease) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 73
Multiple Myeloma (Kahler's Disease) - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 74
Multiple Myeloma (Kahler's Disease) - Pipeline by Santaris Pharma A/S, H1 2014 75
Multiple Myeloma (Kahler's Disease) - Pipeline by Celgene Corporation, H1 2014 76
Multiple Myeloma (Kahler's Disease) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 77
Multiple Myeloma (Kahler's Disease) - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 78
Multiple Myeloma (Kahler's Disease) - Pipeline by MannKind Corporation, H1 2014 79
Multiple Myeloma (Kahler's Disease) - Pipeline by Merck KGaA, H1 2014 80
Multiple Myeloma (Kahler's Disease) - Pipeline by 4SC AG, H1 2014 81
Multiple Myeloma (Kahler's Disease) - Pipeline by EntreMed, Inc., H1 2014 82
Multiple Myeloma (Kahler's Disease) - Pipeline by Gentium S.p.A., H1 2014 83
Multiple Myeloma (Kahler's Disease) - Pipeline by AEterna Zentaris Inc., H1 2014 84
Multiple Myeloma (Kahler's Disease) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014 85
Multiple Myeloma (Kahler's Disease) - Pipeline by Immunomedics, Inc., H1 2014 86
Multiple Myeloma (Kahler's Disease) - Pipeline by Compugen Ltd., H1 2014 87
Multiple Myeloma (Kahler's Disease) - Pipeline by Patrys Limited, H1 2014 88
Multiple Myeloma (Kahler's Disease) - Pipeline by Curis, Inc., H1 2014 89
Multiple Myeloma (Kahler's Disease) - Pipeline by BioInvent International AB, H1 2014 90
Multiple Myeloma (Kahler's Disease) - Pipeline by JW Pharmaceutical Corporation, H1 2014 91
Multiple Myeloma (Kahler's Disease) - Pipeline by Innate Pharma SA, H1 2014 92
Multiple Myeloma (Kahler's Disease) - Pipeline by Transgene Biotek Limited, H1 2014 93
Multiple Myeloma (Kahler's Disease) - Pipeline by Cellerant Therapeutics, Inc., H1 2014 94
Multiple Myeloma (Kahler's Disease) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 95
Multiple Myeloma (Kahler's Disease) - Pipeline by Chroma Therapeutics Ltd., H1 2014 96
Multiple Myeloma (Kahler's Disease) - Pipeline by CIMAB S.A., H1 2014 97
Multiple Myeloma (Kahler's Disease) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 98
Multiple Myeloma (Kahler's Disease) - Pipeline by Acceleron Pharma, Inc., H1 2014 99
Multiple Myeloma (Kahler's Disease) - Pipeline by Priaxon AG, H1 2014 100
Multiple Myeloma (Kahler's Disease) - Pipeline by Hutchison MediPharma Limited, H1 2014 101
Multiple Myeloma (Kahler's Disease) - Pipeline by Vivolux AB, H1 2014 102
Multiple Myeloma (Kahler's Disease) - Pipeline by Altor BioScience Corporation AB, H1 2014 103
Multiple Myeloma (Kahler's Disease) - Pipeline by Coronado Biosciences, Inc., H1 2014 104
Multiple Myeloma (Kahler's Disease) - Pipeline by Vaccinex, Inc., H1 2014 105
Multiple Myeloma (Kahler's Disease) - Pipeline by CanBas Co., Ltd., H1 2014 106
Multiple Myeloma (Kahler's Disease) - Pipeline by Axelar AB, H1 2014 107
Multiple Myeloma (Kahler's Disease) - Pipeline by Onconova Therapeutics, Inc., H1 2014 108
Multiple Myeloma (Kahler's Disease) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2014 109
Multiple Myeloma (Kahler's Disease) - Pipeline by Immune System Therapeutics Ltd., H1 2014 110
Multiple Myeloma (Kahler's Disease) - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 111
Multiple Myeloma (Kahler's Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2014 112
Multiple Myeloma (Kahler's Disease) - Pipeline by Immunocore Limited, H1 2014 113
Multiple Myeloma (Kahler's Disease) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014 114
Multiple Myeloma (Kahler's Disease) - Pipeline by Pharma Mar, S.A., H1 2014 115
Multiple Myeloma (Kahler's Disease) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 116
Multiple Myeloma (Kahler's Disease) - Pipeline by AB Science, H1 2014 117
Multiple Myeloma (Kahler's Disease) - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2014 118
Multiple Myeloma (Kahler's Disease) - Pipeline by CureTech Ltd., H1 2014 119
Multiple Myeloma (Kahler's Disease) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2014 120
Multiple Myeloma (Kahler's Disease) - Pipeline by Janssen Biotech, Inc., H1 2014 121
Multiple Myeloma (Kahler's Disease) - Pipeline by Elara Pharmaceuticals GmbH, H1 2014 122
Multiple Myeloma (Kahler's Disease) - Pipeline by Zyngenia, Inc., H1 2014 123
Multiple Myeloma (Kahler's Disease) - Pipeline by Molecular Templates Inc., H1 2014 124
Multiple Myeloma (Kahler's Disease) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 125
Multiple Myeloma (Kahler's Disease) - Pipeline by Gliknik, Inc., H1 2014 126
Multiple Myeloma (Kahler's Disease) - Pipeline by Celleron Therapeutics Ltd, H1 2014 127
Multiple Myeloma (Kahler's Disease) - Pipeline by Immunovative Therapies, Ltd.., H1 2014 128
Multiple Myeloma (Kahler's Disease) - Pipeline by Targazyme, Inc., H1 2014 129
Multiple Myeloma (Kahler's Disease) - Pipeline by Advancell, H1 2014 130
Multiple Myeloma (Kahler's Disease) - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2014 131
Multiple Myeloma (Kahler's Disease) - Pipeline by Igenica, Inc., H1 2014 132
Multiple Myeloma (Kahler's Disease) - Pipeline by Selvita S.A, H1 2014 133
Multiple Myeloma (Kahler's Disease) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 134
Multiple Myeloma (Kahler's Disease) - Pipeline by APIM Therapeutics AS, H1 2014 135
Multiple Myeloma (Kahler's Disease) - Pipeline by Kancera AB, H1 2014 136
Multiple Myeloma (Kahler's Disease) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014 137
Multiple Myeloma (Kahler's Disease) - Pipeline by OncoPep Inc., H1 2014 138
Multiple Myeloma (Kahler's Disease) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 139
Multiple Myeloma (Kahler's Disease) - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 140
Multiple Myeloma (Kahler's Disease) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 141
Multiple Myeloma (Kahler's Disease) - Pipeline by Modulation Therapeutics, Inc., H1 2014 142
Multiple Myeloma (Kahler's Disease) - Pipeline by AbbVie Inc., H1 2014 143
Multiple Myeloma (Kahler's Disease) - Pipeline by cCAM Biotherapeutics Ltd., H1 2014 144
Multiple Myeloma (Kahler's Disease) - Pipeline by BioNovion B.V., H1 2014 145
Multiple Myeloma (Kahler's Disease) - Pipeline by Senhwa Biosciences, H1 2014 146
Assessment by Monotherapy Products, H1 2014 147
Assessment by Combination Products, H1 2014 148
Number of Products by Stage and Target, H1 2014 151
Number of Products by Stage and Mechanism of Action, H1 2014 159
Number of Products by Stage and Route of Administration, H1 2014 166
Number of Products by Stage and Molecule Type, H1 2014 169
Multiple Myeloma (Kahler's Disease) Therapeutics - Recent Pipeline Updates, H1 2014 422
Multiple Myeloma (Kahler's Disease) - Dormant Projects, H1 2014 551
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..1), H1 2014 552
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..2), H1 2014 553
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..3), H1 2014 554
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..4), H1 2014 555
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..5), H1 2014 556
Multiple Myeloma (Kahler's Disease) - Discontinued Products, H1 2014 557

List of Figures
Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2014 27
Number of Products under Development for Multiple Myeloma (Kahler's Disease) - Comparative Analysis, H1 2014 28
Number of Products under Development by Companies, H1 2014 29
Number of Products under Investigation by Universities/Institutes, H1 2014 38
Comparative Analysis by Late Stage Development, H1 2014 41
Comparative Analysis by Clinical Stage Development, H1 2014 42
Comparative Analysis by Early Stage Products, H1 2014 43
Assessment by Monotherapy Products, H1 2014 147
Assessment by Combination Products, H1 2014 148
Number of Products by Top 10 Target, H1 2014 149
Number of Products by Stage and Top 10 Target, H1 2014 150
Number of Products by Top 10 Mechanism of Action, H1 2014 157
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 158
Number of Products by Top 10 Route of Administration, H1 2014 165
Number of Products by Stage and Top 10 Route of Administration, H1 2014 166
Number of Products by Top 10 Molecule Type, H1 2014 167
Number of Products by Stage and Top 10 Molecule Type, H1 2014 168

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for Lung Cancer: Global Markets

Diagnostics and Therapeutics for Lung Cancer: Global Markets

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research report analyzes the market for diagnostics and therapeutics for lung cancer, and also focuses on regulations and reimbursements affecting diagnostics tests and drugs used in therapeutics. ...

Bladder Cancer Treatment Drugs Markets in China

Bladder Cancer Treatment Drugs Markets in China

  • $ 4 000
  • Industry report
  • June 2015
  • by Asia Market Information & Development Company

China's demand for Bladder Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Cancer Treatment Drugs Markets in China

Cancer Treatment Drugs Markets in China

  • $ 4 000
  • Industry report
  • June 2015
  • by Asia Market Information & Development Company

China's demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...


Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US, Weekly Update

  • July 2015
    12 pages
  • Pathology  

  • United States  

View report >

Pathology Description in the UK

  • July 2015
    2 pages
  • Cancer  

    Oncology  

    Breast Cancer  

  • United Kingdom  

View report >

Cola Markets in the US

  • July 2015
    12 pages
  • Cola  

    Sugar  

    Energy Drink  

  • United States  

    World  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.